Assessing bone marrow changes in children with acute lymphoblastic leukemia using MRI
Clinical Pilot Study of Quantitative MRI Assessment of Bone Marrow in Patients With Acute Lymphoblastic Leukemia and Patients Without Hematopoietic Disorders, From 6 to 18 Years Old
This study is testing if MRI can help track changes in the bone marrow of children with acute lymphoblastic leukemia during their chemotherapy treatment.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 150 (estimated) |
| Ages | 6 Years to 18 Years |
| Sex | All |
| Sponsor | Federal Research Institute of Pediatric Hematology, Oncology and Immunology Academic / other |
| Drugs / interventions | chemotherapy |
| Locations | 1 site (Moscow) |
| Trial ID | NCT04767165 on ClinicalTrials.gov |
What this trial studies
This study evaluates the changes in bone marrow composition in children aged 6 to 18 years diagnosed with acute lymphoblastic leukemia during their chemotherapy treatment. It utilizes quantitative MRI techniques to measure parameters such as the fat-to-water ratio, apparent diffusion coefficient, and T1 relaxation time, providing a non-invasive method to monitor the disease. A control group of healthy children will also be included to compare results. The goal is to establish MRI as a reliable tool for diagnosis and therapy response monitoring in pediatric hematological malignancies.
Who should consider this trial
Good fit: Ideal candidates for this study are children aged 6 to 18 years who are currently undergoing chemotherapy for acute lymphoblastic leukemia.
Not a fit: Patients outside the age range of 6 to 18 years or those who require general anesthesia for MRI will not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide a non-invasive method for monitoring treatment response in children with acute lymphoblastic leukemia.
How similar studies have performed: While the use of MRI in assessing bone marrow is promising, this specific application in pediatric acute lymphoblastic leukemia is relatively novel and has not been extensively tested.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: 1. patients from 6 to 18 years old 2. diagnosis of acute lymphoblastic leukemia during chemotherapy 3. patients of the same age without hematological diseases Exclusion Criteria: 1. patients less then 6, and older then 18 years old 2. patients who cannot perform the study MRI without general anesthesia
Where this trial is running
Moscow
- Dmitry Rogachev National Research Center of Pediatric Hematology, Oncology and Immunology — Moscow, Russian Federation (Recruiting)
Study contacts
- Study coordinator: Nataliia Kriventsova
- Email: nataliya.krivencova@fccho-moscow.ru
- Phone: +7 (495)2876570
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.